{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-alcoholic+Fatty+Liver&page=3",
    "query": {
      "condition": "Non-alcoholic Fatty Liver",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 562,
    "total_pages": 57,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-alcoholic+Fatty+Liver&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-alcoholic+Fatty+Liver&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-05T15:47:07.615Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05729282",
      "title": "Glycemic Effect of Diazoxide in NAFLD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hyperinsulinemia",
        "Insulin Resistance",
        "Non-Alcoholic Fatty Liver Disease",
        "Prediabetic State"
      ],
      "interventions": [
        {
          "name": "Diazoxide oral suspension, 1 mg per kg per dose",
          "type": "DRUG"
        },
        {
          "name": "Diazoxide oral suspension, 2 mg per kg per dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "FreeStyle Libre Pro",
          "type": "DEVICE"
        },
        {
          "name": "Deuterated water (2H2O/D2O)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 22,
      "start_date": "2023-08-01",
      "completion_date": "2025-09-10",
      "has_results": true,
      "last_update_posted_date": "2026-09-30",
      "last_synced_at": "2026-10-05T15:47:07.615Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05729282"
    },
    {
      "nct_id": "NCT04263376",
      "title": "Bariatric Surgery-Induced Shift in Gut Microbiome and NAFLD",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Obesity",
        "Diabetes Mellitus, Type 2",
        "NAFLD"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "The Cleveland Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 18,
      "start_date": "2019-04-24",
      "completion_date": "2022-01-31",
      "has_results": false,
      "last_update_posted_date": "2023-01-05",
      "last_synced_at": "2026-10-05T15:47:07.615Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04263376"
    },
    {
      "nct_id": "NCT03744182",
      "title": "A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "NAFLD"
      ],
      "interventions": [
        {
          "name": "HM15211",
          "type": "DRUG"
        },
        {
          "name": "Placebo of HM15211",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hanmi Pharmaceutical Company Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 66,
      "start_date": "2018-11-01",
      "completion_date": "2020-03-18",
      "has_results": true,
      "last_update_posted_date": "2025-01-27",
      "last_synced_at": "2026-10-05T15:47:07.615Z",
      "location_count": 1,
      "location_summary": "Chula Vista, California",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03744182"
    },
    {
      "nct_id": "NCT03053050",
      "title": "Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Nonalcoholic Steatohepatitis"
      ],
      "interventions": [
        {
          "name": "SEL",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match SEL 6 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match SEL 18 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 808,
      "start_date": "2017-02-13",
      "completion_date": "2019-06-19",
      "has_results": true,
      "last_update_posted_date": "2020-06-29",
      "last_synced_at": "2026-10-05T15:47:07.615Z",
      "location_count": 124,
      "location_summary": "Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 95 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03053050"
    },
    {
      "nct_id": "NCT04480710",
      "title": "A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "NASH - Nonalcoholic Steatohepatitis",
        "Fibrosis, Liver",
        "NAFLD - Nonalcoholic Fatty Liver Disease"
      ],
      "interventions": [
        {
          "name": "CRV431 75mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo (1 softgel)",
          "type": "DRUG"
        },
        {
          "name": "CRV431 225mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo (3 softgels)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hepion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 47,
      "start_date": "2020-06-23",
      "completion_date": "2021-10-30",
      "has_results": true,
      "last_update_posted_date": "2022-07-15",
      "last_synced_at": "2026-10-05T15:47:07.615Z",
      "location_count": 9,
      "location_summary": "Orange, California • Poway, California • Miami, Florida + 5 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Poway",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Port Orange",
          "state": "Florida"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04480710"
    },
    {
      "nct_id": "NCT04210245",
      "title": "Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Compensated Cirrhosis",
        "Nonalcoholic Steatohepatitis"
      ],
      "interventions": [
        {
          "name": "aldafermin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "NGM Biopharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 160,
      "start_date": "2020-03-23",
      "completion_date": "2023-02-23",
      "has_results": true,
      "last_update_posted_date": "2025-03-26",
      "last_synced_at": "2026-10-05T15:47:07.615Z",
      "location_count": 31,
      "location_summary": "Glendale, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 22 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "North Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04210245"
    },
    {
      "nct_id": "NCT03166735",
      "title": "Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-alcoholic Fatty Liver Disease"
      ],
      "interventions": [
        {
          "name": "BI 1467335",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 114,
      "start_date": "2017-06-06",
      "completion_date": "2019-06-14",
      "has_results": true,
      "last_update_posted_date": "2020-06-11",
      "last_synced_at": "2026-10-05T15:47:07.615Z",
      "location_count": 17,
      "location_summary": "Coronado, California • La Jolla, California • La Mesa, California + 13 more",
      "locations": [
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03166735"
    },
    {
      "nct_id": "NCT05499585",
      "title": "Treating Pediatric NAFLD with Nutrition",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Non-Alcoholic Fatty Liver Disease",
        "Liver Diseases",
        "Liver Fat",
        "Hepatic Steatosis",
        "Nutritional and Metabolic Disease"
      ],
      "interventions": [
        {
          "name": "Whole Dairy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "10 Years to 17 Years"
      },
      "enrollment_count": 20,
      "start_date": "2022-09-12",
      "completion_date": "2024-09-10",
      "has_results": false,
      "last_update_posted_date": "2024-09-26",
      "last_synced_at": "2026-10-05T15:47:07.615Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05499585"
    },
    {
      "nct_id": "NCT06528314",
      "title": "A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "NASH - Nonalcoholic Steatohepatitis",
        "MASH - Metabolic Dysfunction-Associated Steatohepatitis"
      ],
      "interventions": [
        {
          "name": "Efruxifermin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Akero Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 2150,
      "start_date": "2024-09-04",
      "completion_date": "2030-03",
      "has_results": false,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-10-05T15:47:07.615Z",
      "location_count": 165,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 139 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Flagstaff",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06528314"
    },
    {
      "nct_id": "NCT02581085",
      "title": "Tocotrienol Against the Progression of End Stage Liver Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "End Stage Liver Disease",
        "NASH - Nonalcoholic Steatohepatitis",
        "NAFLD - Nonalcoholic Fatty Liver Disease"
      ],
      "interventions": [
        {
          "name": "Tocotrienol (TCT)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Chandan Sen",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 110,
      "start_date": "2019-11-01",
      "completion_date": "2025-12-16",
      "has_results": false,
      "last_update_posted_date": "2026-09-08",
      "last_synced_at": "2026-10-05T15:47:07.615Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02581085"
    }
  ]
}